Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Naara Shorook, Kochat Veena, Rao Xiayu, Arslan Emre, Saddawi-Konefka Robert, Satpati Suresh, Garbarino Jennifer, Anderson Jennifer L, Gleber-Netto Frederico O, Nagarajan Priyadharsini, Kerr Travis D, Akhter Shamima, Li Sophie, Fodor R'ay, Koyfman Shlomo A, Yaniv Dan, Xie Tongxin, Glaun Mica, Bobian Michael, Padron William Israel, Ng Colin, Gunaratne Preethi H, Thevasagayampillai Shiyanth, Migden Michael R, Abbas Hussein A, Reville Patrick K, Tsai Kenneth Y, McGrail Daniel J, Wang Jing, Myers Jeffrey N, Gross Neil D, Rai Kunal, Amit Moran
Аннотация
Immunosuppressed patients with non-melanoma skin cancer experience worse clinical outcomes, yet the tumor immune microenvironment associated with systemic immunosuppression remains incompletely defined. Using integrated single-cell, spatial transcriptomic, multiplex immunofluorescence, and spatial epigenomic profiling across immunocompetent and immunosuppressed tumors, we found that overall immune-cell composition was largely preserved despite differences in immune-cell distribution, spatial organization, and T cell clonality. Immunosuppressed tumors demonstrated reduced intratumoral macrophage densities, decreased T cell clonal diversity, altered antigen-presenting cell and T cell spatial interactions, and distinct fibroblast- and macrophage-associated spatial niches. Multi-cohort validation across complementary spatial and single-cell platforms identified consistent alterations in innate-adaptive immune organization in immunosuppressed tumors. Together, these findings define spatial and functional remodeling of the tumor immune microenvironment under systemic immunosuppression and provide a framework for future therapeutic investigation in high-risk patients.